Longevity
NeuroSense splits its ALS drug trial into three to outrun the disease
By Life and Health Today Staff, . Life and Health Today.
NeuroSense Therapeutics, a Cambridge, Massachusetts-based biotech, announced late last month that it is abandoning the conventional single-trial approval path for PrimeC, its lead candidate for ALS (amyotrophic lateral sclerosis, the progressive motor-neuron disease commonly called Lou Gehrig's disease), in favour of three shorter, more focused studies. Longevity.Technology reported the announcement.
The strategic logic is blunt. Most people diagnosed with ALS do not live past three years, according to Longevity.Technology's reporting. Most drugs aiming to treat it spend longer than that moving through a single confirmatory trial. PrimeC has not yet been shown in a completed pivotal trial to slow or stop the disease; the restructuring is an attempt to reach a verdict while patients are still alive to benefit from one.
PrimeC combines two already-approved drugs, ciprofloxacin (an antibiotic) and celecoxib (an anti-inflammatory), into a single extended-release formulation. The rationale, as reported by Longevity.Technology, is that pairing them may address several of ALS's suspected biological drivers at once, including nervous-system inflammation, iron accumulation in neurons, and disrupted RNA regulation, rather than targeting a single mechanism. The novelty is in the combined formulation, not in either drug individually.
The three-part plan works as follows, according to Longevity.Technology. The first piece applies AI-assisted modelling to pharmacokinetic data the company already holds. Pharmacokinetics describes how a drug moves through the body: how fast it is absorbed, how long it stays active, and how consistently that pattern appears across different patients. NeuroSense says its existing data show that PrimeC's specific formulation produces a different, synchronised absorption pattern compared with taking the two drugs separately, and it wants to extract a sharper, more defensible version of that claim from data it already owns rather than running a new study.
The second study is described by Longevity.Technology as the riskier bet: a head-to-head comparison of PrimeC against edaravone, an ALS drug already on the market. Most ALS trials compare a candidate against a placebo. A direct comparison against an approved competitor would, if PrimeC won, provide evidence of a kind that placebo trials cannot, though it also carries clear downside if PrimeC comes up short.
The third piece reshapes PARAGON, the Phase 3 trial (the large confirmatory study typically required before approval) that NeuroSense already has FDA clearance to run. The redesigned version would be smaller, shorter, and enrol patients earlier in their disease course. NeuroSense says it intends to ask the FDA whether existing data could support full approval outright, or whether accelerated approval, which allows earlier access in exchange for a required follow-up study, is the more realistic path. The FDA has not yet responded to that question, and the redesigned pivotal trial has not been approved.
NeuroSense has also completed a pre-submission process with Health Canada and is targeting a formal filing there by December, a track that could, according to Longevity.Technology, put PrimeC in Canadian patients' hands before the US process concludes.
What this announcement does not establish is whether PrimeC works. The evidence base described is pharmacokinetic and mechanistic, not a completed efficacy trial in people with ALS. The head-to-head study against edaravone has not yet been run. The redesigned pivotal trial has not been approved by the FDA. CEO Alon Ben-Noon is quoted by Longevity.Technology as saying the plan is "faster, it costs less and it produces a stronger package" than the single-trial approach, but that is a claim about trial design, not about clinical outcomes.
The open question is whether the FDA will accept the redesigned PARAGON trial and, if it does, whether PrimeC will show a meaningful benefit in that compressed, earlier-enrolment population. Those answers are not available yet. Anyone weighing what this means for a specific patient should discuss it with a neurologist who knows that patient's situation.
Source: https://longevity.technology/news/neurosense-splits-one-big-als-trial-into-three/